アンチセンスオリゴヌクレオチド（ASO）：Innovation Insights

アンチセンスオリゴヌクレオチド（ASO）は、特定のmRNA配列に結合するように設計されたDNAまたはRNAの短い合成鎖であり、それによって遺伝子発現を調節します。ASOは、リボヌクレアーゼH（RNase H）を介した分解、立体的なブロック、スプライシングの調節といったメカニズムで機能します。ASOは遺伝子疾患、がん、炎症性疾患などのさまざまな疾患の治療に有望視されています。注目すべき例としては、Sareptaの脊髄性筋萎縮症治療薬や、デュシェンヌ型筋ジストロフィー向けのEteplirsenなどがあります。ASO化学の進歩により、安定性、特異性、デリバリーが向上し、治療可能性が高まっています。

アンチセンスオリゴヌクレオチド（ASO）はバイオ医薬品の一種であり、近い将来の影響の大きいイノベーションとして大きな注目を集めています。これらの医薬品はmRNAや遺伝子の発現を変化させるために使用され、治療効果をもたらします。特許分析によると、ASOは主に大学と公開製薬企業によって推進されており、米国がイノベーション活動を主導しています。

ASO治療情勢は少数の企業に集中しており、Sarepta、Ionis、Opko Health（Camp4）の特許数がもっとも多いです。SareptaとIonisは特許ポートフォリオの強さの指標でも上位にあります。興味深いことに、中国での活動は限られており、この分野の特許を持つ中国企業は1社しか確認されていません。

スタートアップでは、Remix Therapeuticsが首位で、Ractigen、Secarna Pharmaがそれに続きます。スタートアップの大半は中国外に拠点を置いていますが、ASO分野では中国に拠点を置くスタートアップが3社確認されています。Kastle Therapeuticsは、Ionis Pharmaから特定のASO療法を商業化する独占ライセンスを得ています。

ASOの医薬品情勢は、がんと中枢神経系（CNS）の治療に重点を置いた革新的な医薬品が優位にあります。Ionis Pharma、Sarepta Therapeutic Inc、AstraZeneca、Biogen Incなどの主要企業が、特に前臨床試験やフェーズII試験において医薬品開発をリードしています。このことは、近い将来の市場参入の可能性を秘めたパイプラインが成熟しつつあることを示しています。

当レポートでは、アンチセンスオリゴヌクレオチド（ASO）について調査分析し、特許、医薬品、臨床試験、取引に関する包括的なデータを提供しています。

目次

第1章 イノベーションの考察

• イノベーションレーダー
• イノベーションSカーブ
• イノベーションの詳細
• イノベーションの詳細 - 流行の適応症
• ポートフォリオの強さと時間的指標に基づく主要企業

第2章 競合考察

• 主なイノベーションリーダー - 大手製薬企業
• 主なイノベーター - スタートアップ、小規模バイオテクノロジー企業
• 主なイノベーション - 大学、研究機関
• もっとも引用された特許
• AIハブからの考察

第3章 市場の考察

• 医薬品
  • 主要企業
  • 投与経路・医薬品タイプ
  • 主な治療分野・適応症
• 臨床試験
  • 主なスポンサー
  • 主な開発段階
• 取引
  • 主な買収者
  • 取引タイプの分布
  • 地理的分布

Antisense oligonucleotides (ASOs) are short, synthetic strands of DNA or RNA designed to bind to specific mRNA sequences, thereby modulating gene expression. They work through mechanisms such as RNase H-mediated degradation, steric blocking, and modulation of splicing. ASOs have shown promise in treating various diseases, including genetic disorders, cancers, and inflammatory conditions. Notable examples include Sarepta therapeutics for spinal muscular atrophy and eteplirsen for Duchenne muscular dystrophy. Advances in ASO chemistry have improved their stability, specificity, and delivery, enhancing therapeutic potential. In report, which includes comprehensive data on patents, drugs, clinical trials, and deals, provides a valuable resource for understanding the current landscape and future directions in ASO therapy.

Antisense oligonucleotides (ASO) are a class of biological medicines that have gained significant attention as a high-impact innovation in the near-term. These medicines are used to alter the expression of mRNA and genes, offering therapeutic benefits. The patent analysis reveals that ASOs are primarily driven by universities and public-listed pharmaceutical companies, with the United States leading in terms of innovation activity.

The ASO therapeutics landscape is concentrated among a smaller set of companies, with Sarepta, Ionis, and Opko Health (Camp4) having the highest number of patents. Sarepta and Ionis also rank highly in terms of patent portfolio strength indicators. Interestingly, there is limited activity in China, with only one China-based company identified with patents in this area.

In terms of startups, Remix Therapeutics leads the pack, followed by Ractigen and Secarna Pharma. While the majority of startups are based outside of China, there are three China-based startups identified in the ASO space. Kastle Therapeutics has an exclusive license from Ionis Pharma for commercializing certain ASO therapies.

The drug landscape for ASOs is dominated by innovator drugs, with a strong focus on oncology and central nervous system (CNS) therapies. Major players like Ionis Pharma, Sarepta Therapeutic Inc, AstraZeneca, and Biogen Inc are leading the way in drug development, particularly in preclinical and phase II trials. This suggests a maturing pipeline with potential for market entry in the near future.

Key Highlights

• Antisense oligonucleotides (ASO) are a high-impact innovation in the pharmaceutical industry, with the potential to alter gene expression and mRNA using various mechanisms for therapeutic purposes.
• The patent analysis indicates that ASO innovation is primarily driven by universities and public-listed pharmaceutical companies, with the United States being the leading geography in terms of activity. However, there is a growing trend of academy-industry collaborations driving innovation in ASOs.
• The ASO therapeutics landscape is concentrated among a limited number of companies, with Sarepta, Ionis, and Opko Health (Camp4) having the highest number of patents. Sarepta and Ionis also rank highly in terms of patent portfolio strength indicators. There is limited activity in China, with only one China-based company identified with patents in this area.
• Startups in the ASO field, such as Remix Therapeutics, Ractigen, and Secarna Pharma, are emerging as key players in innovation and development. While the majority of startups are based outside of China, there are three China-based startups identified in the ASO space.
• The drug landscape for ASOs is dominated by innovator drugs, with a strong focus on oncology and central nervous system (CNS) disorders. Major pharmaceutical companies like Ionis Pharma, Sarepta Therapeutic Inc, AstraZeneca, and Biogen Inc are leading the way in drug development, particularly in preclinical and phase II trials.

Scope

• Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.
• Key player: This Represents a sample list of key players in each use case highlighted in the report.
• Startups: This represents a sample list of emaging startups in each use case highlighted in the report.
• University: This Represents a sample list of leading universities in each use case highlighted in the report.

Reasons to Buy

• No surprise that technology has been a driving force in business transformation for years, but the term 'emerging technologies' has all of the sudden become the key catalyst to drive the next wave of innovation across sectors.
• Antisense oligonucleotides (ASOs) provides comprehensive insights into the latest advancements, market analysis, and competitive intelligence. It helps in strategic planning by offering detailed data on patents, drugs, clinical trials, and deals. The report keeps you updated on regulatory and clinical developments, crucial for navigating the healthcare landscape. Additionally, it identifies investment opportunities by analyzing financial deals and funding trends, ensuring you stay ahead in the field. This information is valuable for making informed business decisions and understanding the activities of top pharmaceutical companies, startups, and universities.

Table of Contents

Table of Contents

1. Innovation Insights

• 1.1 Innovation radar
• 1.2 Innovation s-curve
• 1.3 Innovation deep dive
• 1.4 Innovation deep dive - trending indications
• 1.5 Top companies Based on portfolio strength and temporal indicators

2. Competitive Insights

• 2.1 Key innovation leaders - big pharma
• 2.2.Key innovators - startups and small biotech
• 2.3 Key innovations - Universities and research institutions
• 2.4 Most cited patents
• 2.5 Insights from AI hub

3.Market Insights

• 3.1 Drugs
  • 3.1.1 Key Players
  • 3.1.2 Route of administration & drug type
  • 3.1.3 Top therapy area & indication
• 3.2 Clinical Trials
  • 3.2.1 Key Sponsors
  • 3.2.2 Key development stages
• 3.3 Deals
  • 3.3.1. Key Acquirers
  • 3.3.2 Deal type distribution
  • 3.3.3 Geographical distribution